245 related articles for article (PubMed ID: 20657595)
1. Matriptase initiates activation of epidermal pro-kallikrein and disease onset in a mouse model of Netherton syndrome.
Sales KU; Masedunskas A; Bey AL; Rasmussen AL; Weigert R; List K; Szabo R; Overbeek PA; Bugge TH
Nat Genet; 2010 Aug; 42(8):676-83. PubMed ID: 20657595
[TBL] [Abstract][Full Text] [Related]
2. SPINK5 knockdown in organotypic human skin culture as a model system for Netherton syndrome: effect of genetic inhibition of serine proteases kallikrein 5 and kallikrein 7.
Wang S; Olt S; Schoefmann N; Stuetz A; Winiski A; Wolff-Winiski B
Exp Dermatol; 2014 Jul; 23(7):524-6. PubMed ID: 24848304
[TBL] [Abstract][Full Text] [Related]
3. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity.
Descargues P; Deraison C; Bonnart C; Kreft M; Kishibe M; Ishida-Yamamoto A; Elias P; Barrandon Y; Zambruno G; Sonnenberg A; Hovnanian A
Nat Genet; 2005 Jan; 37(1):56-65. PubMed ID: 15619623
[TBL] [Abstract][Full Text] [Related]
4. Proteolytic activation cascade of the Netherton syndrome-defective protein, LEKTI, in the epidermis: implications for skin homeostasis.
Fortugno P; Bresciani A; Paolini C; Pazzagli C; El Hachem M; D'Alessio M; Zambruno G
J Invest Dermatol; 2011 Nov; 131(11):2223-32. PubMed ID: 21697885
[TBL] [Abstract][Full Text] [Related]
5. Physiological and pathological roles of kallikrein-related peptidases in the epidermis.
Kishibe M
J Dermatol Sci; 2019 Aug; 95(2):50-55. PubMed ID: 31279501
[TBL] [Abstract][Full Text] [Related]
6. Netherton syndrome: defective kallikrein inhibition in the skin leads to skin inflammation and allergy.
Furio L; Hovnanian A
Biol Chem; 2014 Sep; 395(9):945-58. PubMed ID: 25153381
[TBL] [Abstract][Full Text] [Related]
7. Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model.
Briot A; Lacroix M; Robin A; Steinhoff M; Deraison C; Hovnanian A
J Invest Dermatol; 2010 Dec; 130(12):2736-42. PubMed ID: 20703245
[TBL] [Abstract][Full Text] [Related]
8. Genetic activation of Nrf2 reduces cutaneous symptoms in a murine model of Netherton syndrome.
Muzumdar S; Koch M; Hiebert H; Bapst A; Gravina A; Bloch W; Beer HD; Werner S; Schäfer M
Dis Model Mech; 2020 Jun; 13(5):. PubMed ID: 32457102
[TBL] [Abstract][Full Text] [Related]
9. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome.
Briot A; Deraison C; Lacroix M; Bonnart C; Robin A; Besson C; Dubus P; Hovnanian A
J Exp Med; 2009 May; 206(5):1135-47. PubMed ID: 19414552
[TBL] [Abstract][Full Text] [Related]
10. Netherton syndrome: skin inflammation and allergy by loss of protease inhibition.
Hovnanian A
Cell Tissue Res; 2013 Feb; 351(2):289-300. PubMed ID: 23344365
[TBL] [Abstract][Full Text] [Related]
11. The identification of a new role for LEKTI in the skin: The use of protein 'bait' arrays to detect defective trafficking of dermcidin in the skin of patients with Netherton syndrome.
Bennett K; Heywood W; Di WL; Harper J; Clayman GL; Jayakumar A; Callard R; Mills K
J Proteomics; 2012 Jul; 75(13):3925-37. PubMed ID: 22588119
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor signaling induces the expression of lympho-epithelial Kazal-type inhibitor in epidermal keratinocytes.
Sugimoto S; Morizane S; Nomura H; Kobashi M; Sugihara S; Iwatsuki K
J Dermatol Sci; 2018 Nov; 92(2):181-187. PubMed ID: 30270115
[TBL] [Abstract][Full Text] [Related]
13. Reddish, scaly, and itchy: how proteases and their inhibitors contribute to inflammatory skin diseases.
Meyer-Hoffert U
Arch Immunol Ther Exp (Warsz); 2009; 57(5):345-54. PubMed ID: 19688185
[TBL] [Abstract][Full Text] [Related]
14. LEKTI is localized in lamellar granules, separated from KLK5 and KLK7, and is secreted in the extracellular spaces of the superficial stratum granulosum.
Ishida-Yamamoto A; Deraison C; Bonnart C; Bitoun E; Robinson R; O'Brien TJ; Wakamatsu K; Ohtsubo S; Takahashi H; Hashimoto Y; Dopping-Hepenstal PJ; McGrath JA; Iizuka H; Richard G; Hovnanian A
J Invest Dermatol; 2005 Feb; 124(2):360-6. PubMed ID: 15675955
[TBL] [Abstract][Full Text] [Related]
15. Identification of lympho-epithelial Kazal-type inhibitor 2 in human skin as a kallikrein-related peptidase 5-specific protease inhibitor.
Meyer-Hoffert U; Wu Z; Schröder JM
PLoS One; 2009; 4(2):e4372. PubMed ID: 19190773
[TBL] [Abstract][Full Text] [Related]
16. Cathelicidin represents a new target for manipulation of skin inflammation in Netherton syndrome.
Zingkou E; Pampalakis G; Sotiropoulou G
Biochim Biophys Acta Mol Basis Dis; 2020 Oct; 1866(10):165831. PubMed ID: 32442469
[TBL] [Abstract][Full Text] [Related]
17. A proinflammatory role of KLK6 protease in Netherton syndrome.
Zingkou E; Pampalakis G; Charla E; Nauroy P; Kiritsi D; Sotiropoulou G
J Dermatol Sci; 2019 Jul; 95(1):28-35. PubMed ID: 31255470
[TBL] [Abstract][Full Text] [Related]
18. Transgenic Kallikrein 14 Mice Display Major Hair Shaft Defects Associated with Desmoglein 3 and 4 Degradation, Abnormal Epidermal Differentiation, and IL-36 Signature.
Gouin O; Barbieux C; Leturcq F; Bonnet des Claustres M; Petrova E; Hovnanian A
J Invest Dermatol; 2020 Jun; 140(6):1184-1194. PubMed ID: 32169475
[TBL] [Abstract][Full Text] [Related]
19. Dual antibody inhibition of KLK5 and KLK7 for Netherton syndrome and atopic dermatitis.
Chavarria-Smith J; Chiu CPC; Jackman JK; Yin J; Zhang J; Hackney JA; Lin WY; Tyagi T; Sun Y; Tao J; Dunlap D; Morton WD; Ghodge SV; Maun HR; Li H; Hernandez-Barry H; Loyet KM; Chen E; Liu J; Tam C; Yaspan BL; Cai H; Balazs M; Arron JR; Li J; Wittwer AJ; Pappu R; Austin CD; Lee WP; Lazarus RA; Sudhamsu J; Koerber JT; Yi T
Sci Transl Med; 2022 Dec; 14(675):eabp9159. PubMed ID: 36516271
[TBL] [Abstract][Full Text] [Related]
20. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome.
Hachem JP; Wagberg F; Schmuth M; Crumrine D; Lissens W; Jayakumar A; Houben E; Mauro TM; Leonardsson G; Brattsand M; Egelrud T; Roseeuw D; Clayman GL; Feingold KR; Williams ML; Elias PM
J Invest Dermatol; 2006 Jul; 126(7):1609-21. PubMed ID: 16601670
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
